Evidence map›Paper›PMID 35366155›Full record

ReviewCancer metastasis reviews2022

Connecting the Human Microbiome and Pancreatic Cancer.

Rachel E Sexton, Md Hafiz Uddin, Sahar Bannoura, Husain Yar Khan, Yousef Mzannar, Yiwei Li, Amro Aboukameel, Mohammad Najeeb Al-Hallak, Bayan Al-Share, Amr Mohamed and 3 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer metastasis reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Article
  11. Inflammation, microbiota, and pancreatic cancer.Cancer cell international · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Rachel E SextonDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Md Hafiz UddinDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Sahar BannouraDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Husain Yar KhanDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Yousef MzannarDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Yiwei LiDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Amro AboukameelDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Mohammad Najeeb Al-HallakDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Bayan Al-ShareDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Amr MohamedUH Seidman Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Misako NagasakaUniversity of California, Irvine, UCI Health Chao Family Comprehensive Cancer Center, CA, Irvine, USA.
Bassel El-RayesO'Neal Comprehensive Cancer Center, University of Alabama, AL, Tuscaloosa, USA.
Asfar S AzmiDepartment of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA. azmia@karmanos.org.

Funding

Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic CancerR37CA215427 · NCI · WAYNE STATE UNIVERSITY · PI AZMI, ASFAR S · 2018 to 2024
$2.4M
A novel therapy for pancreatic neuroendocrine tumorsR01CA240607 · NCI · WAYNE STATE UNIVERSITY · PI AZMI, ASFAR S, EL-RAYES, BASSEL · 2020 to 2024
$1.7M
NCI NIH HHS R01 CA240607NCI NIH HHS R37 CA215427
6 · The paper itself

Abstract

Pancreatic cancer is a deadly disease that is increasing in incidence throughout the world. There are no clear causal factors associated with the incidence of pancreatic cancer; however, some correlation to smoking, diabetes and alcohol has been described. Recently, a few studies have linked the human microbiome (oral and gastrointestinal tract) to pancreatic cancer development. A perturbed microbiome has been shown to alter normal cells while promoting cancer-related processes such as increased cell signaling, immune system evasion and invasion. In this article, we will review in detail the alterations within the gut and oral microbiome that have been linked to pancreatic cancer and explore the ability of other microbiomes, such as the lung and skin microbiome, to contribute to disease development. Understanding ways to identify a perturbed microbiome can result in advancements in pancreatic cancer research and allow for prevention, earlier detection and alternative treatment strategies for patients.

Indexed as

MicrobiotaPancreatic NeoplasmsHumansPancreasHuman MicrobiomeOncogenesisPancreatic Cancer

Identifiers

PMID35366155
PMCPMC8976105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.